Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
Opus Genetics announced it will present topline data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 gene therapy targeting BEST1-related inherited retinal diseases. The data presentation is scheduled for September 9, 2026, followed by full clinical datasets at major ophthalmology conferences. OPGx-BEST1 uses an AAV vector to deliver a functiona…